Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Riboflavin
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Glaukos Announces FDA Acceptance of NDA Submission for Epioxa™
Details : Epioxa (riboflavin) is a small molecule drug candidate, which is being evaluated for the treatment of patients with progressive keratoconus.
Product Name : Epioxa
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
February 24, 2025
Lead Product(s) : Riboflavin
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Riboflavin
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Glaukos Submits New Drug Application to U.S. FDA for Epioxa™
Details : Epioxa (riboflavin) is a small molecule drug candidate, which is being evaluated for the treatment of patients with progressive keratoconus.
Product Name : Epioxa
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
December 23, 2024
Lead Product(s) : Riboflavin
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Riboflavin
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Glaukos Achieves Primary Endpoint in Phase 3 Epioxa™ Trial for Tolerability
Details : Epioxa (riboflavin) is a small molecule drug candidate, which is being evaluated for the treatment of patients with progressive keratoconus.
Product Name : Epioxa
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
October 16, 2024
Lead Product(s) : Riboflavin
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Riboflavin
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Epithelium-On Corneal Cross-linking in Subjects 8 to 45 Years of Age With Keratoconus
Details : Undisclosed
Product Name : Undisclosed
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
October 25, 2023
Lead Product(s) : Riboflavin
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Riboflavin
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Epithelium-On Corneal Cross-linking in Subjects 8 to 45 Years of Age with Keratoconus
Details : Undisclosed
Product Name : Undisclosed
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
October 25, 2023
Lead Product(s) : Riboflavin
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Riboflavin
Therapeutic Area : Undisclosed
Study Phase : Undisclosed
Sponsor : Atlantia Food Clinical Trials
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
April 07, 2023
Lead Product(s) : Riboflavin
Therapeutic Area : Undisclosed
Highest Development Status : Undisclosed
Sponsor : Atlantia Food Clinical Trials
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Riboflavin
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Undisclosed
Sponsor : Royal DSM
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
August 04, 2022
Lead Product(s) : Riboflavin
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Undisclosed
Sponsor : Royal DSM
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Riboflavin
Therapeutic Area : Ophthalmology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Safety and Efficacy of Corneal Cross-linking in Subjects With Keratoconus
Details : Undisclosed
Product Name : Undisclosed
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
April 06, 2022
Lead Product(s) : Riboflavin
Therapeutic Area : Ophthalmology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Riboflavin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
February 24, 2022
Lead Product(s) : Riboflavin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Riboflavin
Therapeutic Area : Ophthalmology
Study Phase : Phase II/ Phase III
Sponsor : Cornea Research Foundation of America
Deal Size : Inapplicable
Deal Type : Inapplicable
Corneal Crosslinking for Treatment of Corneal Neovascularization
Details : Undisclosed
Product Name : Undisclosed
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
March 08, 2021
Lead Product(s) : Riboflavin
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II/ Phase III
Sponsor : Cornea Research Foundation of America
Deal Size : Inapplicable
Deal Type : Inapplicable